Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk’s Wegovy Outperforms Eli Lilly’s Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s (NYSE:LLY) tirzepatide treatment in people with…

Read More
The Conversation

What And How You Eat Can Increase Levels Of GLP-1 Without Drugs

(© gstockstudio – stock.adobe.com) Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides. Increased intakes…

Read More